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Abstract 15 
Oxygen sensing mechanisms are vital for homeostasis and survival. When oxygen levels are too low 16 
(hypoxia), blood flow has to be increased, metabolism reduced, or a combination of both, to 17 
counteract tissue damage. These adjustments are regulated by local, humoral or neural reflex 18 
mechanisms. The kidney and the carotid body are both directly sensitive to falls in the partial 19 
pressure of oxygen and trigger reflex adjustments and thus act as oxygen sensors. We hypothesize a 20 
cooperative oxygen sensing function by both the kidney and carotid body to ensure maintenance of 21 
whole body blood flow and tissue oxygen homeostasis. Under pathological conditions of severe or 22 
prolonged tissue hypoxia, these sensors may become excessively activated continuously and increase 23 
perfusion pressure chronically. Consequently, persistence of their activity could become a driver for 24 
the development of hypertension and cardiovascular disease. Hypoxia-mediated renal and carotid 25 
body afferent signaling triggers unrestrained activation of the renin angiotensin-aldosterone system 26 
(RAAS). Renal and carotid body mediated responses in arterial pressure appear to be synergistic as 27 
interruption of either afferent source has a summative effect of reducing blood pressure in 28 
renovascular hypertension. We discuss that this cooperative oxygen sensing system can 29 
activate/sensitize their own afferent transduction mechanisms via interactions between the RAAS, 30 
hypoxia inducible factor and erythropoiesis pathways. This joint mechanism supports our view point 31 
that the development of cardiovascular disease involves afferent nerve activation.  32 
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1 Introduction 33 
Oxygen is essential for aerobic metabolism, a fundamental mechanism for energy production. 34 
However, the delivery of optimal levels of oxygen to tissues must be highly regulated as both 35 
insufficient (hypoxia) or excessive oxygen levels (hyperoxia) are highly detrimental. Indeed, tissue 36 
oxygenation has been found to be reduced during pathological conditions such as cancer (Liu, Zhao 37 
et al. 2016), diabetes (Palm, Cederberg et al. 2003), hypertension (Welch, Baumgartl et al. 2001), 38 
chronic kidney disease (Milani, Ansaloni et al. 2016) and stroke (Ferdinand and Roffe 2016). We 39 
will explore the idea that an inappropriate activation of some of the signaling pathways that 40 
counteract hypoxia can contribute to the development of hypertension and cardiovascular disease 41 
through activation of the sympathetic nervous system.  42 
Adaptation to low partial pressure of oxygen, for instance at high altitude, triggers a protective 43 
mechanism that includes an increase in sympathetic activity, vascular resistance and blood pressure 44 
(Hainsworth and Drinkhill 2007). The kidney and carotid body both participate in this adaptation for 45 
the maintenance of systemic oxygen levels and blood flow (Marshall 1994, Dunn, Lo et al. 2007, 46 
Jelkmann 2011). For example, within the kidney the number of erythropoietin-producing cells 47 
increases proportionally to the degree of hypoxia, which correlates directly with the concentration of 48 
erythropoietin in blood (Koury and Haase 2015), ensuring higher blood oxygen carrying capacity 49 
(Marshall 1994, Dunn, Lo et al. 2007, Jelkmann 2011). In comparison, the carotid body triggers 50 
reflex increases ventilation and sympathetic activity to maintain oxygen tension and delivery 51 
(Marshall 1994). Interestingly the kidney and the carotid body are both innervated by efferent and 52 
afferent nerve fibers and are both targets and modulators of sympathetic activity. Hypoxic-53 
hypoperfusion of the kidney and carotid body is a likely trigger for increased reflex sympathetic 54 
activity (Koeners, Lewis et al. 2016) and aberrant afferent drive from these organs is implicated in 55 
the etiology of neurogenic hypertension (Fisher and Paton 2012, Narkiewicz, Ratcliffe et al. 2016, 56 
Silva, Costa et al. 2016, Osborn and Foss 2017).  57 
We wish to explore whether there is cooperative oxygen sensing between the kidney and the carotid 58 
body that plays a role in homeostasis. We will consider this notion under physiological conditions 59 
where it counteracts moderate or brief tissue hypoxia over an acute short time scale (minutes to 60 
hours). We will also assess the long term (days) cooperative oxygen sensing where hypoxia afferent 61 
signaling from these organs persists and drives the progression of cardiovascular disease. We initiate 62 
our discussion by examining the effect of short and long term hypoxia on the kidney and carotid 63 
body. 64 
 65 
2. Hypoxia, afferent nerve activation/sensitization and hypertension 66 
2.1 Hypoxia 67 
Oxygen delivery to different organs is a product of cardiac output and arterial oxygen content per 68 
unit of time (Habler and Messmer 1997, Leach and Treacher 2002). The majority of oxygen 69 
transported throughout the body is reversibly bound to hemoglobin, and its diffusion to the cell is 70 
dependent on the local tissue partial pressure gradient. Oxygen consumption in a given tissue is the 71 
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volume of oxygen consumed per unit of time, which in aerobic conditions corresponds to the 72 
metabolic rate (adenosine triphosphate (ATP) formation/consumption) (Habler and Messmer 1997, 73 
Leach and Treacher 2002). Each organ has a different metabolic rate, and hence a different oxygen 74 
demand. Every organ has the capacity of altering their metabolic rate (except skin), as part of the 75 
local dynamics which, in most cases, directly influences local blood flow. Due to an oxygen reserve, 76 
oxygen consumption is independent of oxygen delivery within a wide range of delivered oxygen. In 77 
addition, organs have different oxygen extraction ratios (fraction of oxygen delivery) and different 78 
oxygen reserves. Organs that have a lower oxygen extraction, such as the skin, have a higher oxygen 79 
venous reserve. Conversely, the heart and the brain have a limited oxygen reserve due to the high 80 
oxygen extraction (Habler and Messmer 1997). In case of systemic low oxygen delivery or systemic 81 
high oxygen demand, blood can be redistributed to sustain high extraction organs, without 82 
compromising oxygen supply to the ones with higher oxygen reserves. However, increases in oxygen 83 
consumption or decreases in oxygen delivery will increase oxygen extraction to maintain aerobic 84 
metabolism. When the critical oxygen delivery limit is reached, any increase in oxygen consumption 85 
or decrease in oxygen delivery will lead to tissue hypoxia, as reviewed in (Leach and Treacher 2002).  86 
The term hypoxia represents a reduced partial pressure of oxygen and deoxygenation of tissue. Such 87 
a condition triggers a series of responses that manifest themselves over different sequential time 88 
frames: First, acute systemic reduction of tissue oxygen partial pressure stimulates peripheral 89 
chemoreceptors that triggers respiratory and cardiovascular responses to elevate oxygen uptake and 90 
delivery to bodily organs (Lahiri, Nishino et al. 1980, Marshall 1994, Blessing, Yu et al. 1999). 91 
Second, persistent subacute hypoxia activates cellular pathways through the stabilization of hypoxia 92 
inducible factor (HIF)-1 and HIF-2 complexes (Greer, Metcalf et al. 2012). HIF-1 is understood to be 93 
the most important regulator of cellular responses to hypoxia. This long term adaptation is triggered 94 
in order to enhance the oxygen delivery capacity and maintain organ function, including glycolysis, 95 
angiogenesis, erythropoiesis, iron metabolism, pH regulation, apoptosis, cell proliferation as well as 96 
cell-cell and cell-matrix interactions (Haase 2006, Greer, Metcalf et al. 2012). Examples of classic 97 
HIF target genes are phosphoglycerate kinase-1, glucose transporter-1, vascular endothelial growth 98 
factor, and erythropoietin. Pathologic conditions like renal disease and diabetic nephropathy have 99 
shown to impede this adaptation via, for example, desensitization of renal erythropoietin-producing 100 
cells by uremic toxins (Chiang, Tanaka et al. 2012) or direct inhibition of HIF activity (Nordquist, 101 
Friederich-Persson et al. 2015, Tanaka, Tanaka et al. 2016). Indeed, treatment which increased HIF 102 
activity corrected abnormal renal metabolism (oxygen consumption, efficiency) and hemodynamics 103 
(renal blood flow, glomerular filtration) in a rat model of chronic kidney disease (Deng, Arndt et al. 104 
2010). Interestingly these effects were similar to RAAS inhibition but involved a significantly 105 
different molecular pathway. Third, chronic sustained tissue hypoxia can result from stenosis/partial 106 
occlusion of conduit arteries that may be of congenital or atherosclerotic origin. In case of 107 
obstruction of blood flow ischemic injury will follow due to the reduced nutrient and oxygen supply. 108 
As proposed previously (Koeners, Lewis et al. 2016), hypoxic-hypoperfusion may trigger aberrant 109 
renal and/or carotid body afferent tonicity and initiate/amplify sympathetic hyperactivity 110 
accentuating arteriolar vasoconstriction and further compounding blood flow and oxygen delivery; 111 
this results in hypertension. 112 
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2.2 Renal oxygenation 113 
Renal oxygenation is tightly regulated (both short and long term) to maintain the balance between 114 
oxygen supply and demand. Under normal conditions, but under anesthesia, renal partial pressure of 115 
oxygen varies from 15-50 mmHg in the cortex and 5-25 mmHg in the renal medulla (Evans, 116 
Gardiner et al. 2008, Carreau, El Hafny-Rahbi et al. 2011). Due to the unique anatomy of the kidney, 117 
the renal medulla is believed to receive the minimum level of oxygen needed to support normal cell 118 
function, and hence might be very susceptible to reductions of the partial pressure of oxygen.  119 
The heterogeneous oxygenation within the renal parenchyma is a result of the different tasks 120 
performed along the nephron and is mainly associated with: 1) the high energy demand necessary to 121 
reabsorb Na+, 2) the arteriovenous oxygen shunt and 3) the requirements to perform the 122 
countercurrent mechanism that permits urine concentration. Almost all of the renal oxygen 123 
consumption is coupled with active Na+ transport through Na-K-ATPase (Mandel and Balaban 124 
1981). To put this in perspective, the energy required to reabsorb 1 mol Na+ is approximately 7 kj, 125 
which corresponds to lifting 1 mol Na+ (~20g) to a height of 70 km (Hansell, Welch et al. 2013). In 126 
addition, the development of a Na+ gradient allows the transport of other molecules such as glucose, 127 
amino-acids, other solutes and water. Since the reabsorption of Na+ depends on the glomerular 128 
filtration rate, increasing the blood flow to the kidney will increase the filtered Na+ load and further 129 
deplete renal oxygen due to a higher oxygen consumption (Hansell, Welch et al. 2013). Another 130 
factor contributing to the oxygen content in the renal tissue is the arteriovenous oxygen shunt. The 131 
renal arteries and veins run in close proximity, oxygen can diffuse in such a way that the oxygen 132 
content in the veins is higher than that in the glomerular capillaries and efferent arterioles (Schurek, 133 
Jost et al. 1990, Welch, Baumgartl et al. 2001, Evans, Gardiner et al. 2008). This is especially 134 
important when considering that the renal medullary peritubular capillaries arise from the efferent 135 
arterioles of the juxtamedullary glomeruli. This vessel network also has a low blood flow to maintain 136 
the gradients necessary for the countercurrent mechanism that allows urine concentration (Brezis and 137 
Rosen 1995, Fry, Edwards et al. 2014). Furthermore, the close proximity of the ascending and 138 
descending medullary vasa recta may theoretically promote more arteriovenous oxygen diffusion 139 
(Zhang and Edwards 2002). Hence, the renal medulla has a relative low partial pressure of oxygen 140 
and is highly susceptible to ischemic/hypoxic injury.  141 
As already indicated above the kidney contributes to long-term (days) hypoxic adaptation. It has a 142 
primordial role in maintaining systemic oxygen content through hypoxia-induced erythropoietin 143 
production from the renal interstitial fibroblast-like cells. Under hypoxia, HIF-α is no longer 144 
hydroxylated, and HIF-α subunits can accumulate to activate HIF-1-dependent genes like 145 
erythropoietin and many others (Haase 2006). Erythropoietin acts on bone marrow to increase red 146 
blood cell production (Dunn, Lo et al. 2007, Jelkmann 2011) which will increase the oxygen carrying 147 
capacity. Therefore, the kidney serves as one of the most important physiological oxygen sensors and 148 
detectors of systemic hypoxia. 149 
 150 
 151 
 152 
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2.3 Renal hypoxia, afferent nerve activation/sensitization and hypertension 153 
Chronic hypoxia has been confirmed in different kidney disease models such as diabetic nephropathy 154 
(Palm, Cederberg et al. 2003) and hypertension (Welch, Baumgartl et al. 2001). Long term renal 155 
hypoxia is an increasingly recognized common pathway for the development of chronic kidney 156 
disease (Hansell, Welch et al. 2013, Kawakami, Mimura et al. 2014), but it can also generate renal 157 
injury. Friederich-Persson et al showed that increasing kidney oxygen metabolism, using a 158 
mitochondrial uncoupler, reduces the cortical partial pressure of oxygen and causes proteinuria in 159 
otherwise healthy rats (Friederich-Persson, Thorn et al. 2013).  160 
Acute renal hypoxia may also be involved in the activation of renal afferent pathways that leads to 161 
the establishment and maintenance of elevated blood pressure. The cell bodies of the renal afferent 162 
nerve fibers are located in the dorsal root ganglia and project to the ipsilateral dorsal horn where they 163 
synapse with neurons projecting to sites associated with cardiovascular regulation such as the nucleus 164 
tractus solitarii and the rostral ventral medulla (Solano-Flores, Rosas-Arellano et al. 1997, Ciriello 165 
and de Oliveira 2002, Kopp 2015) where integration with other inputs will occur and reflex 166 
sympathetic responses can be generated. Indeed, perfusion of the kidney with hypoxic blood (PaO2: 167 
36 mmHg) is enough to increase femoral perfusion pressure by >30 mmHg. This response is 168 
mediated by renal afferent nerves as it was abolished after denervating the kidney (Ashton, Clarke et 169 
al. 1994). However, whether there is a threshold, or graded thresholds of renal tissue partial oxygen 170 
pressure for renal afferent nerve activation is unknown. Furthermore, performing the same 171 
experiment using normoxic blood and ischemic metabolites such as bradykinin, prostaglandin E2 and 172 
adenosine elicits similar rises in blood pressure (Ashton, Clarke et al. 1994). This demonstrates that 173 
both low partial pressure of oxygen and ischemic metabolites can directly and/or indirectly stimulate 174 
renal sensory nerve fibers, promoting reflex increase of the sympathetic nerve activity and blood 175 
pressure (Katholi, McCann et al. 1985).  176 
In the two-kidney one clip model of hypertension, denervation of the hypoperfused (clipped) kidney 177 
reduced arterial blood pressure, noradrenaline plasma concentration and peripheral sympathetic nerve 178 
activity (Katholi, Whitlow et al. 1982). Similarly, in the one-kidney, one-clip model of renovascular 179 
hypertension, dorsal root rhizotomy ipsilateral to the clipped kidney attenuated the evoked 180 
hypertension (Wyss, Aboukarsh et al. 1986). Importantly, even a small lesion in the kidney that 181 
results in an area(s) of ischemia (hypoperfusion) not necessarily affecting renal function, e.g. by 182 
intrarenal injection of phenol, can cause neurogenic hypertension via activation of hypoxia-sensitive 183 
renal afferent mechanisms (Ye, Zhong et al. 2002, Koeners, Vink et al. 2014). In this phenol model 184 
of renal neurogenic hypertension there is a rapid (within 5 minutes) and sustained increase in blood 185 
pressure that is abolished by nephrectomy or denervation of the injured kidney (Ye, Zhong et al. 186 
2002, Koeners, Vink et al. 2014). These studies support the concept that hypoxia-induced renal 187 
afferent activation contributes to hypertension by increasing sympathetic nerve activity through 188 
reflex pathways. Similarly, in patients with renovascular hypertension, restoration of renal perfusion 189 
reduces muscle sympathetic nerve activity and blood pressure (Miyajima, Yamada et al. 1991) and 190 
renal nerve ablation can reduce blood pressure and muscle sympathetic nerve activity in some 191 
patients with resistant hypertension (Hering, Marusic et al. 2014). Finally, given the change in set-192 
point of sympathetic activity and blood pressure it is perhaps not surprising that the baroreceptor 193 
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reflex is reset and gain improved following renal denervation in a rat model of chronic kidney disease 194 
(Chen, Cheng et al. 2016). 195 
We suggest that the aforementioned renal afferent reflex pathway impinging on the nucleus tractus 196 
solitarii is a likely nodal point for modulation of the baroreflex. Taken together, both acute or chronic 197 
renal hypoxia and hypoperfusion (associated with macro- or microvascular disease) may 198 
cause/sustain hypertension through activation of renal afferent chemosensory fibers (Campese, Mitra 199 
et al. 2006, Johns, Kopp et al. 2011, Foss, Wainford et al. 2015, Banek, Knuepfer et al. 2016). This 200 
has parallels with sustained activation of the peripheral chemoreceptors, which are considered next. 201 
 202 
2.4. Carotid body oxygenation 203 
Carotid bodies are distinct organs located bilaterally at the bifurcation of the common carotid arteries. 204 
They have the highest blood flow per tissue weight when compared to any other organ in the body 205 
and play an important role in the monitoring and maintenance of physiological levels of blood gases 206 
through reflex activation of respiration (Lahiri, Nishino et al. 1980). The carotid body consists of 207 
glomus or type I cells, which are the primary oxygen sensing cells, and supporting or type II cells. 208 
Blood supply to the carotid body originates mostly from the carotid artery. The carotid body 209 
vasculature is innervated by postganglionic sympathetic fibers from the superior cervical ganglion 210 
and by parasympathetic fibers originating from intraglomic ganglion cells. With larger blood vessels 211 
having predominantly parasympathetic innervation and smaller blood vessels having predominantly 212 
sympathetic innervation, as reviewed by (Kumar and Prabhakar 2012). Hence, the arterioles that are 213 
in close contact with the type I and type II cells are predominantly innervated with sympathetic 214 
fibers, thus more prone to vasoconstriction/hypoperfusion that promotes chemoreceptor activation.  215 
The blood supply to the carotid body is very high given the total metabolic demand, with less than 216 
3% of oxygen consumed (De Burgh Daly, Lambertsen et al. 1954). Of interest, tissue partial pressure 217 
of oxygen is lower than that measured in the venous blood, suggesting the existence of an 218 
arteriovenous shunt, with potentially a large amount of blood bypassing the chemosensory cells 219 
(Acker, Lubbers et al. 1971, Acker and O'Regan 1981, O’Regan, Ennis et al. 1990).  Despite the very 220 
low total organ oxygen consumption, type I cells have a very high metabolic rate with an oxygen 221 
consumption at rest approaching the maximum (Duchen and Biscoe 1992). This very high oxygen 222 
consumption makes type I cells very sensitive to reductions in partial pressure of oxygen.  223 
The microvascular partial pressure of oxygen in the carotid body is around 50-70 mmHg in the 224 
anaesthetised cat (Whalen, Savoca et al. 1973, Rumsey, Iturriaga et al. 1991). It has been shown that 225 
changes in oxygenation below this level results in a powerful increase in carotid body afferent 226 
activity (Vidruk, Olson et al. 2001). Neurosecretion from the glomus cells within the carotid body in 227 
response to acute hypoxia is fundamental to chemosensation and involves release of a variety of 228 
molecules including acetylcholine, dopamine, ATP, and neuropeptides such as substance P or 229 
enkephalins have been investigated. Recently, evidence for gas signalling molecules such as nitric 230 
oxide and carbon monoxide have been highlighted in the carotid body for oxygen sensing (Prabhakar 231 
2000, Nurse and Piskuric 2013). These transmitters all activate the terminals of afferent fibers at the 232 
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glomus cell-afferent junction. Anatomical studies on the cat carotid region revealed that glomus cells 233 
are innervated both by sensory and autonomic fibers mostly from the carotid sinus nerve but also by 234 
superior cervical ganglion and occasionally the ganglio-glomerular nerves (Eyzaguirre and Uchizono 235 
1961, Knoche and Kienecker 1977).  236 
2.5 Carotid body hypoxia, afferent nerve activation/sensitization and hypertension 237 
Chemoreceptor activation typically occurs after a change in arterial partial oxygen pressure from ~95 238 
mmHg to ~50 mmHg for a single unit chemoreceptor in vitro (Vidruk and Dempsey 1980), and to 239 
~35 mmHg for a whole nerve in vivo (Vidruk, Olson et al. 2001). However chemoreceptor afferent 240 
fibers show huge variability in their threshold of activation to hypoxia permitting graded responses 241 
(Vidruk, Olson et al. 2001) and therefore is likely to overlap with renal afferent threshold(s). It has 242 
also been proposed that carotid body glomus cells and associated sensory fibers have reflex specific 243 
circuits that account for different patterns of response evoked by different stimulants or different 244 
levels of hypoxia (acute or chronic) (Paton, Ratcliffe et al. 2013). Importantly, the afferent nerves of 245 
the different sub-populations of glomus cells may project into compartmentalized sites of the nucleus 246 
tractus solitarii that regulate cardiac, respiratory, sympathetic as well has higher brain functions 247 
(Paton, Ratcliffe et al. 2013). Carotid body chemoreceptor activation leads to an increased 248 
sympathetic tone through glutamatergic excitatory signalling in the nucleus tractus solitarii, rostral 249 
ventrolateral medulla and the paraventricular nucleus resulting in increased blood pressure (Marshall 250 
1994, Blessing, Yu et al. 1999).  251 
The carotid chemoreflex plays a powerful role in the blood pressure regulation including modulation 252 
of renal function. For example, carotid chemoreflex activation using autologous venous blood, while 253 
maintaining carotid sinus pressure constant, reduced renal blood flow and glomerular filtration rate 254 
through increased renal nerve activation in dogs (Karim et al. 1987). For a long time it has been 255 
considered that carotid bodies only change blood pressure over seconds. However, recently an 256 
increasing amount of evidence suggests that persistent stimulation of the carotid body might play a 257 
role in long-term blood pressure control. In hypertensive animals and humans, chemo-sensory fibers 258 
are continuously activated causing increased vasomotor sympathetic activity and hypertension in 259 
animals and humans (Sinski, Lewandowski et al. 2014, Pijacka, Moraes et al. 2016). To demonstrate 260 
carotid body tonicity, the carotid sinus nerves were resected and this was found to attenuate the 261 
developmental increase in the blood pressure in young spontaneously hypertensive animals (Abdala, 262 
McBryde et al. 2012). In addition, carotid sinus denervation performed in adult spontaneously 263 
hypertensive rats reduced blood pressure and sympathetic activity chronically; it also led to increased 264 
aortic baroreflex sensitivity (Abdala, McBryde et al. 2012, McBryde, Abdala et al. 2013). These 265 
animal studies were translated into a first human study with similar results in some hypertensive 266 
patients (Narkiewicz, Ratcliffe et al. 2016).  267 
This evidence suggests that excessive afferent signalling from carotid bodies may lead to the 268 
development of pathological conditions such as hypertension in animals and human. However, what 269 
triggers carotid body tonicity is still poorly understood but it is unlikely to be systemic hypoxia. The 270 
possibility that the carotid body is chronically hypoxic, perhaps due to hypoperfusion secondary to 271 
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either increased sympathetic vasomotor tone or circulating angiotensin II is plausible, at least in 272 
hypertension.  273 
3. Kidney and carotid body: cooperative oxygen sensors  274 
As outlined above acute and chronic hypoxia is sensed by both the kidney and the carotid body that 275 
activates afferent nerve signalling promoting reflex increases in sympathetic nerve activity triggering 276 
hypertension (Katholi, Whitlow et al. 1982, Tafil-Klawe, Trzebski et al. 1985, Somers, Mark et al. 277 
1988, Ashton, Clarke et al. 1994, Ye, Zhong et al. 2002, Campese, Mitra et al. 2006, Tan, Lu et al. 278 
2010, Johns, Kopp et al. 2011, Abdala, McBryde et al. 2012, Sinski, Lewandowski et al. 2012, 279 
McBryde, Abdala et al. 2013, Paton, Sobotka et al. 2013, Koeners, Vink et al. 2014, Foss, Wainford 280 
et al. 2015, Banek, Knuepfer et al. 2016, Pijacka, McBryde et al. 2016, Pijacka, Moraes et al. 2016). 281 
We hypothesize that the response to systemic hypoxia is based on both local renal and carotid body 282 
specific chronic hypoxia sensing which act cooperatively (see Box). Given the greater sensitivity of 283 
the kidney to hypoxia (see above) we propose that this organ responds first to falls in arterial oxygen 284 
tension. As oxygen tension falls further signals cascading from the kidney activate the carotid body 285 
and its recruited acts cooperatively to ensure sustained long term sympathoexcitation. Evidence for 286 
this cooperative mechanism comes from the additive blood pressure lowering effect after renal 287 
denervation is performed in combination with carotid body de-afferentation/resection (McBryde, 288 
Abdala et al. 2013, McBryde, Hart et al. 2016, Pijacka, McBryde et al. 2016, McBryde, Hart et al. 289 
2017). The carotid sinus and the renal afferent nerves converge in multiple central cardiovascular 290 
regulation areas, providing an anatomical basis for interaction such as the nucleus tractus solitarii and 291 
the rostral ventrolateral medulla (Johns, Kopp et al. 2011).  292 
 293 
3.1. Lines of communication: kidney to carotid body 294 
Given their relative sensitivities to acute and chronic hypoxia it would seem logical to postulate a 295 
communication cascade from the kidney to the carotid body (Figure 1). This might include the 296 
RAAS. The RAAS plays a key role in cardiovascular and renal physiology and is primarily activated 297 
as a functional response to maintain organ perfusion. Most of the RAAS effects arise from 298 
angiotensin II AT1 receptor activation and include direct vasoconstriction, increased tubular sodium 299 
reabsorption, activation of sympathetic nervous system and increased aldosterone release, fibrosis, 300 
reactive oxygen species production and cell proliferation (Balakumar and Jagadeesh 2014). 301 
Accordingly, the RAAS is currently the main pharmacological target of anti-hypertensive therapy 302 
(Romero, Orias et al. 2015). Their mechanism seems straight forward: reduce or block angiotensin II 303 
and aldosterone, thereby preventing the deleterious cardiovascular effects. However, RAAS 304 
inhibition is also effective in patients with medium-to low plasma RAAS activity (Te Riet, van Esch 305 
et al. 2015). Moreover, after inhibiting angiotensin II/aldosterone receptors, plasma levels of these 306 
two hormones returns to normal or even rise above pre-treatment levels: the so-called angiotensin II 307 
escape/ refractory hyperaldosteronism (Te Riet, van Esch et al. 2015). Remarkably, RAAS inhibition 308 
remains partially anti-hypertensive (Te Riet, van Esch et al. 2015). Experimental evidence shows that 309 
intra-renal RAAS is compartmentalized from systemic RAAS; for example, intrarenal RAAS is not 310 
adequately inhibited by plasma concentrations of RAAS inhibition in currently used dosages 311 
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(Nishiyama, Seth et al. 2002). Whether this RAAS compartmentalization occurs in other organs, like 312 
the carotid body, and is immune to systemic RAAS antagonists is unknown.  313 
If the carotid body is an additional source of afferent drive contributing to sympathetic excess in 314 
conditions of hypertension, then what drives it? Certainly, all the components of the RAAS have 315 
been identified in the carotid body, except renin (Allen 1998, Lam and Leung 2002, Lam and Leung 316 
2003). Interestingly a high density of angiotensin II receptors, type 1 are located on the primary 317 
chemoreceptor element, the glomus cell (Allen 1998) and their expression and function is 318 
upregulated when exposed to chronic hypoxia (Leung, Lam et al. 2000). We hypothesize that this 319 
forms a line of communication to amplify the generation of sympathetic activity. We do not rule out 320 
that in renovascular hypertension heightened sympathetic activity to the carotid body itself (causing 321 
vasoconstriction, hypoperfusion) results in enhanced carotid body discharge and elevated systemic 322 
RAAS activity. We will address the proposed role of RAAS and cooperative oxygen sensing in the 323 
kidney and carotid body. 324 
3.1.1 Hypoxia and renal renin-angiotensin aldosterone system in hypertension  325 
Renal sympathetic activation constricts the renal vasculature thus reducing renal blood flow and 326 
glomerular filtration rate, increases sodium retention and activates the RAAS through increased renin 327 
release from the juxtaglomerular cells (DiBona 2000, Johns, Kopp et al. 2011). Angiotensin II AT1 328 
receptor activation affects oxygen availability in the kidney by acting on both its delivery 329 
(vasoconstriction) and consumption (increased metabolic rate, decreased efficiency or both). 330 
Angiotensin II-induced reduction in renal blood flow is associated with the reduction of partial 331 
pressure of oxygen in the renal cortex (Welch, Blau et al. 2005, Emans, Janssen et al. 2016). 332 
Interestingly, in the two kidney one clip model of renovascular hypertension, renal angiotensin II is 333 
increased in both kidneys from the first week post clipping (Sadjadi, Puttaparthi et al. 2002). This 334 
suggests that the induced hypoxic-hypoperfusion in the ipsi-lateral kidney also activates the RAAS in 335 
the contra-lateral kidney (perhaps via a renorenal reflex) in the development of renovascular 336 
hypertension in this model.  337 
By increasing angiotensin II within the kidney, HIF and erythropoiesis pathways may be triggered to 338 
increase oxygen delivery systemically. This in line with the fact that angiotensin II infusion reduces 339 
cortical partial pressure of oxygen (Welch, Blau et al. 2005, Emans, Janssen et al. 2016) and 340 
increases erythropoietin production in the kidney (Gossmann, Burkhardt et al. 2001, Jelkmann 2011, 341 
Calo, Davis et al. 2015). Once active, the HIF and erythropoiesis pathways act as feedforward 342 
mechanisms. For instance, the increased renal angiotensin II further exaggerates the efferent 343 
sympathetic input and sodium retention by abolishing the renorenal reflex, as reviewed by (Johns, 344 
Kopp et al. 2011). We cannot exclude that aldosterone also plays a role in our hypothesised 345 
cooperative oxygen sensing and blood pressure control. Increased aldosterone secretion is associated 346 
with hypertension (Laragh, Ulick et al. 1960, Mackenzie and Connell 2006). Clinical studies have 347 
shown that aldosterone blockade is the most effective add-on drug (step 4 treatment in the NICE 348 
guidelines www.nice.org.uk/Guidance/CG127) for the treatment of resistant hypertension (Epstein 349 
I  r vi
ew
   Hypoxia in Hypertension 
 
11 
and Duprez 2016). However, the role of the mineralcorticoid receptor in relation with cooperative 350 
sensing of hypoxia by the kidney and carotid body is completely unknown.  351 
Taken together, activation of renal afferents (discussed previously) and the RAAS act as two distinct 352 
feedback systems during acute and chronic hypoxia sensing by the kidney. As hypoxia is relative to 353 
physiological tissue oxygen pressure these feedback systems are likely to have overlapping hypoxia 354 
thresholds for their activation and play intricate roles in both acute and/or chronic changes in tissue 355 
oxygenation.  356 
3.1.2 Carotid body and renin-angiotensin aldosterone system in hypertension 357 
Locally generated angiotensin II increases carotid body afferent discharge (Lam and Leung 2002) 358 
and increases the intracellular calcium levels via activation of AT1 receptors in carotid body type I 359 
(Fung, Lam et al. 2001) and type II (Murali, Zhang et al. 2014) cells. Murali and coworkers 360 
hypothesized that angiotensin II AT1 receptor-mediated pannexin-1 channel dependent ATP release 361 
in type II cells serves as a boost for carotid body excitation (Murali, Zhang et al. 2014), which may 362 
be specially relevant in conditions where local angiotensin II is elevated such as chronic heart failure 363 
(Li, Xia et al. 2006), sleep apnea (Lam, Liu et al. 2014) and in the hypertensive state. Chronic 364 
hypoxia induces angiotensin II AT1 receptor expression in the carotid body (Lam, Liu et al. 2014). 365 
Blockade of angiotensin II AT1 receptors prevents chronic intermittent hypoxia-mediated reactive 366 
oxygen species production in the carotid body (Lam, Liu et al. 2014) and the development of 367 
hypertension (Fletcher, Bao et al. 1999). In fact, angiotensin II AT1 receptor activation has been 368 
shown to induce sensory long term facilitation of the carotid body via NADPHoxidase (Peng, 369 
Raghuraman et al. 2011). Importantly, in chronic intermittent hypoxia, carotid body afferent nerve 370 
activation is also mediated by angiotensin II AT1 receptors (Marcus, Li et al. 2010). Moreover, 371 
reducing the blood flow (hypoxic-hypoperfusion) to carotid body by carotid artery occlusion elevated 372 
angiotensin II AT1 receptor expression in carotid body and increased chemoreceptor activity in the 373 
rabbit (Ding, Li et al. 2011). Activation of angiotensin II AT1 receptor in vitro (hence independently 374 
of vasoconstriction) by AngII activated afferent chemoreceptor activity (Allen 1998). Importantly, 375 
blocking angiotensin II AT1 receptor receptors in isolated carotid body blunts angiotensin II AT1 376 
receptor -dependent carotid body sensitivity (Li, Gao et al. 2007).  377 
Many mechanisms govern carotid body signaling, including ATP-gated ion channels (called 378 
purinergic P2X receptors), specifically the C-fiber-localized, P2X3-receptor subtypes, which are 379 
commonly associated with afferent sensitization and might contribute to hyper-reflexic disease states 380 
in a variety of organs. We found that in spontaneously hypertensive rats P2X3 receptors are 381 
upregulated and that blockade of P2X3 receptors was effective at reducing blood pressure and 382 
sympathetic activity in the spontaneously hypertensive rats but had no effect in normotensive control 383 
rats (Pijacka, Moraes et al. 2016). Interestingly chronic angiotensin II infused hypertensive rats have 384 
upregulated intrarenal P2X1 receptors (Franco, Bautista et al. 2011).  385 
Taken together this underlines the important role RAAS in carotid body can play in hypoxia sensing, 386 
possibly via purineric signaling. Potentially the kidney could trigger the carotid body via RAAS 387 
activation, compounding renal sympathetic activity (driving renal afferents) which will exaggerate 388 
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RAAS activity. If this is true a continued carotid body drive could be deleterious to the kidney 389 
causing over excitation of renal afferents, genomic changes, resulting in a double wind up of the 390 
systems and ultimately cause persistent hypertension.  391 
4. Commonality in the HIF pathway and its role in cooperative oxygen sensing by the kidney 392 
and carotid body 393 
When tissue oxygen levels drop chronically, expression of the HIF-1α and -1β subunits increase. The 394 
HIF-1 α/β heterodimer binds and activates expression of various genes including those encoding 395 
glycolytic enzymes (for anaerobic metabolism), vascular endothelial growth factor (for 396 
angiogenesis), inducible nitric oxide synthase and heme oxygenase-1 (for production of 397 
vasodilators), erythropoietin (for erythropoiesis), and possibly tyrosine hydroxylase (for dopamine 398 
production to increase breathing) (Guillemin and Krasnow 1997). These genes help the cell survive at 399 
low oxygen and act to restore normal oxygen levels.  400 
In the normal, fully developed kidney, HIF-1α is expressed in most cell types, whereas HIF-2α is 401 
mainly found in renal interstitial fibroblast-like cells and endothelial cells. The HIF pathway has been 402 
implicated with renal development, normal kidney function and disease (Haase 2006). Recently 403 
HIF-1α mRNA has been suggested to be a potential biomarker in chronic kidney disease, and comes 404 
primarily from cells of renal origin (Movafagh, Raj et al. 2017). Interestingly, the carotid body 405 
glomus cells constitutively overexpress HIFs and certain HIF transcriptional targets that are normally 406 
part of the counteractive mechanism against the negative impacts of sustained hypoxia (Zhou, Chien 407 
et al. 2016). Specifically, the glomus cells transcriptionally upregulate atypical mitochondrial 408 
electron transfer chain components, suggesting unique mitochondria are present in the carotid body 409 
and may be responsible for oxygen sensing (Zhou, Chien et al. 2016).  410 
A few years ago, Gassmann and Soliz postulated that there was a crosstalk between the ventilatory 411 
and erythropoietin responses and suggested that the chemoreflex pathway may be activated by 412 
circulating erythropoietin (Brines, Grasso et al. 2004, Gassmann and Soliz 2009).  In fact, circulating 413 
erythropoietin, acting on its receptors present in the carotid body improves  the hypoxic ventilatory 414 
response (Soliz, Joseph et al. 2005) suggesting a key role of erythropoietin for hypoxia adaption 415 
beyond the classical regulation of erythropoiesis (Pichon, Jeton et al. 2016). Interestingly, in models 416 
of chronic and intermittent hypoxia, erythropoietin and its receptor are upregulated in the carotid 417 
body which may promote enhanced excitability and contribute to the pathophysiology of breathing 418 
disorders (Lam, Tipoe et al. 2009).  419 
Balanced expression of the HIF-α isoforms is essential for the correct functioning of oxygen sensing 420 
in the carotid body (Yuan, Peng et al. 2013, Prabhakar and Semenza 2016). HIF-1α is expressed in 421 
both type I and type II cells of the carotid body, while HIF-2α is only expressed in type I cells (Roux, 422 
Brismar et al. 2005).  The carotid body chemoreflex response to acute and chronic hypoxia is blunted 423 
when HIF-1α expression is reduced (Kline, Peng et al. 2002, Yuan, Khan et al. 2011, Yuan, Peng et 424 
al. 2013). Conversely, acute and chronic hypoxic sensitivity is enhanced when HIF-2α is reduced 425 
(Nanduri, Wang et al. 2009, Peng, Nanduri et al. 2011, Yuan, Peng et al. 2013). The balance between 426 
the two isoforms may be implicated in the genesis of aberrant signalling during pathology. For 427 
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instance, intermittent hypoxia in rodents is associated with increased HIF-1α and reduced HIF-2α 428 
protein in the carotid body (Nanduri, Wang et al. 2009). In these conditions, carotid body 429 
chemoreceptor signalling to the adrenal medulla selectively upregulates HIF-1α expression, inducing 430 
catecholamine secretion and blood pressure rise (Peng, Yuan et al. 2014, Kumar, Peng et al. 2015), 431 
the latter is eliminated by adrenal demedullation (Bao, Metreveli et al. 1997). Restoring the levels of 432 
HIF-2α also prevents oxidative stress and blood pressure increase during intermittent hypoxia 433 
exposure (Nanduri, Wang et al. 2009). This demonstrates the contribution of HIF-1α pathway in the 434 
carotid body and its influence in increasing blood pressure. 435 
As angiotensin II stimulates the HIF-1α pathway (see for example (Imanishi, Tomita et al. 2014, Luo, 436 
Zhang et al. 2015)) RAAS activation could potentially cause an imbalance between HIF-α isoforms 437 
in the carotid body. This is supported by the fact that carotid body sensitivity is reduced when 438 
angiotensin II AT1 receptors are blocked (see discussion above) (Li, Gao et al. 2007). Whether there 439 
is a direct link between HIF and erythropoiesis pathways with the cooperative oxygen sensing by the 440 
kidney and carotid body, is unknown and will be off great interest to be studied in further detail. 441 
 442 
5. Clinical perspective 443 
Our hypothesis on the cooperative oxygen sensing by the kidney and carotid body in blood pressure 444 
control could be of great relevance in the pursuit of novel ways to treat hypertension and 445 
cardiovascular disease (see Box). Reducing or eliminating the activity of the carotid body specifically 446 
is emerging as a viable target in diseases in which there is autonomic imbalance such as hypertensive 447 
conditions. Potentially, in resistant hypertensive patients that do not respond to renal denervation, 448 
concomitant elimination of carotid body activity could have a therapeutic benefit, as proposed by 449 
McBryde et al (McBryde, Hart et al. 2016). Currently, surgical removal of the carotid body is the 450 
only way to reduce carotid body activity chronically in humans. Targeting aberrant hypoxia-mediated 451 
activation of renal and carotid body afferent activity would be potentially highly effective clinically.  452 
Hydrogen sulfide, H2S, a gaseous endogenous signaling molecule, is increasingly identified to be 453 
involved in numerous cardiovascular (patho)physiology (Snijder, Frenay et al. 2014, Snijder, Frenay 454 
et al. 2015, Xie, Gu et al. 2016, Huang, Shen et al. 2017, Merz, Stenzel et al. 2017). In the kidney, 455 
H2S exerts significant diuretic, natriuretic and kaliuretic effects by raising glomerular filtration rate 456 
and inhibiting tubular sodium re-absorption (Xia, Chen et al. 2009). In the renal medulla, H2S acts as 457 
an oxygen sensor where its accumulation in hypoxic conditions helps to restore oxygen balance by 458 
increasing medullary blood flow, reducing energy requirements for Na+ transport and directly 459 
inhibiting mitochondrial respiration (Beltowski 2010). Interestingly both low H2S levels and 460 
mitochondrial dysfunction have been found in humans (Granata, Zaza et al. 2009, Perna and Ingrosso 461 
2012) and in animal models (Aminzadeh and Vaziri 2012, Perna and Ingrosso 2012, Gong, Mao et al. 462 
2016) with cardiovascular disease. However, it remains to be established if intervention aimed to 463 
improve H2S levels, e.g. AP39, which proved to specifically increase H2S in the mitochondria 464 
(Ahmad, Olah et al. 2016, Chatzianastasiou, Bibli et al. 2016) can alleviate tissue hypoxia and reduce 465 
blood pressure. 466 
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Pre-clinical and clinical evidence suggests that Finerenone, a next-generation non-steroidal 467 
dihydropyridine-based aldosterone antagonist, may achieve equivalent organ-protective effects with 468 
fewer adverse effects and reduced levels of electrolyte disturbance (Kolkhof, Delbeck et al. 2014, 469 
Bramlage, Swift et al. 2016). The latter is important for its potential applicability for patient with 470 
impaired renal function. This in combination with the above mentioned unknowm relation of the 471 
mineralcorticoid receptor with cooperative sensing of hypoxia by the kidney and carotid body invites 472 
for further pre-clinical research of Finerenone for the treatment of cardiovascular and renal 473 
hypertensive disease.  474 
The argument can be made that pharmacological intervention that mimics and enhances natural, 475 
physiological response to disease may be preferable to single protein regulation. A promising 476 
approach to protect organisms against hypoxia, is upregulation of HIFs, which results in a broad and 477 
coordinated downstream reaction, possibly increasing cellular tolerance to hypoxia and thereby 478 
alleviating the double windup of RAAS and sympathetic hyperactivity that is responsible to the 479 
hypertensive state. Indeed, pre-conditioning by HIFα protein stabilization conferred protection in 480 
several models of acute renal ischemia (Bernhardt, Gottmann et al. 2009, Jarmi and Agarwal 2009, 481 
Yang, Lin et al. 2009, Wang, Schley et al. 2012, Koeners, Vink et al. 2014). Furthermore, HIF 482 
stabilizing compounds are currently being investigated in clinical trials as a treatment for anemia 483 
(Pergola, Spinowitz et al. , Besarab, Chernyavskaya et al. 2016, Holdstock, Meadowcroft et al. 484 
2016). However, a major concern for clinical use includes the “broad pharmacology” of HIF 485 
stabilization due to the upregulation of many genes, including proteins that have been targeted for 486 
inhibition by marketed drugs (e.g.: vascular endothelial growth factor, cyclooxygenase -2), in all 487 
tissues some of which may not be hypoxic. A potential way to circumvent unwanted effects of 488 
systemic HIF stabilization is to develop novel hypoxia activated pro-drugs, which are currently under 489 
development for targeting hypoxia in cancer therapy (Wilson and Hay 2011). Hypothetically these 490 
pro-drugs will only be activated in specifically targeted hypoxic tissues like kidney and/or carotid 491 
body and thereby being able to alleviate hypoxia-mediated renal and carotid body afferent signalling, 492 
unrestrained RAAS activation and hence reduce blood pressure in hypertension. 493 
Theoretically, all these therapies are effective only in patients whose have prolonged and/or severe 494 
tissue hypoxia. We know that, for example in the kidney, tissue oxygenation can vary wildly within 495 
and between individuals and follows a diurnal pattern. The latter, possibly due to variations in oxygen 496 
delivery, which is known to be determined by renal blood flow and peaks in the active phase (Emans, 497 
Janssen et al. 2017), can act as cue for circadian clock genes via the HIF pathway (Adamovich, Ladeuix 498 
et al. 2017). Thus, it is important to identify patients with tissue hypoxia, i.e. more responsive to 499 
hypoxia-oriented therapies. We believe that Magnetic Resonance Imaging (MRI) like blood 500 
oxygenation-level dependent (BOLD) MRI (Pruijm, Milani et al. 2016) and hyperpolarised MRI 501 
(Laustsen 2016) represent very exciting tools to help us to elucidate the role of tissue oxygen 502 
metabolism in hypertension and other cardiovascular diseases.   503 
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Box: Novel insights of the cooperative oxygen sensing by the kidney and carotid body in blood 933 
pressure control 934 
  935 
• Integration of renal and carotid body afferent activity act together to regulate blood 
pressure during both acute and chronic hypoxia.   
 
• The interaction between the kidney and the carotid body is cooperative – not facilitatory 
or occlusive. 
 
• The afferent systems of the kidney and the carotid body may have overlapping thresholds 
for detecting reduced tissue oxygen partial pressure. 
 
• Given the postulated overlap in thresholds, there may be a temporal sequence to the reflex 
responses elicited between the two organs. 
 
• The cooperative oxygen sensing by the kidney and carotid body could be of great 
relevance in the pursuit of novel ways to treat diseases in which there is sympathetic 
overdrive. 
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Figure 1: Schematic representation of the hypothesis that chronic hypoxia sensed by carotid body and 936 
kidney is essential for physiological adaptation and when over-activated can contribute to 937 
cardiovascular disease due to positive cross-organ interactive feedback mechanisms. We propose a 938 
temporal sequence to the reflex responses elicited between the two organs. One potential way of how 939 
the transition from one state to the other would occur includes the inability of the kidney to overcome 940 
tissue hypoxia during pathological conditions related to hypoperfusion and/or increased metabolic rate 941 
(e.g. vasoconstriction, mitochondrial dysfunction, hyperfiltration).  Signals cascading from the hypoxic 942 
kidney activate the carotid body that acts cooperatively to ensure sustained and in the end aberrant long 943 
term sympathoexcitation. Furthermore, the renin angiotensin system is activated in both organs in 944 
response to low blood flow/hypoxia. This chronic low blood flow/hypoxia together with the activation 945 
of the renin angiotensin system forms a nonfunctional positive feedback loop that leads to tissue 946 
damage.  Increasing the renin angiotensin system will lead to activation of different pathways to ensure 947 
proper oxygen delivery, including hypoxia inducible factor and erythropoiesis, that may also contribute 948 
to the dysfunctional sympathetic activation in hypertension 949 
 950 
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